Peroxisome proliferator-activated receptors β/δ: Emerging roles for a previously neglected third family member

Current Opinion in Lipidology

Volumn 14, Issue 2, 2003, Pages 129-135

  Michalik, Liliane ^a   Desvergne, Béatrice ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cell differentiation; Cell survival; Embryonic development; Lipid metabolism; Peroxisome proliferator activated receptor

Indexed keywords

FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CELL TYPE; COLON CARCINOGENESIS; COLORECTAL CANCER; EMBRYO DEVELOPMENT; ENERGY; FATTY ACID METABOLISM; GENE SILENCING; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SENSOR; SKIN DISEASE; TRANSCRIPTION REGULATION;

ANIMALS; COLONIC NEOPLASMS; HUMANS; INFLAMMATION; LIPID METABOLISM; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0037396839     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200304000-00003     Document Type: Review

References (31)

1. Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294:1866-1870. An excellent review on the general principles that govern the action of bioactive lipids and their nuclear receptors, which function as lipid sensors that respond to varying lipid levels, and whose coordinated action on gene expression generates a high level of metabolic control.
2. Desvergne B, Michalik L, Wahli W. Sensors for metabolic control: a regulatory network of nuclear receptors. In: Hormone signaling, chap 14. Goffin V, Kelly PA, editors. Norwell, MA: Kluwer Academic Publishers; 2002. pp. 283-304.
3. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002; 59:790-798.
4. Xu HE, Lambert MH, Montana VG, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 2001; 98:13919-13924. An elegant discussion, on the basis of the crystal structure of the ligand-binding domain of the three PPAR isetypes, of the structural basis for the subtype selectivity of ligand binding.
5. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002; 62:3282-3288. This paper outlines the upregulation of PPARβ expression and activity in K-Ras-transformed intestinal epithelial cells as a result of an increased activity of mitogen-activated protein kinase and the endogenous production of prostacyclin.
6. Wolfrum C, Borrmann CM, Borchers T, et al. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001; 98:2323-2328. The paper provides evidence for the role of fatty acid binding proteins as a mandatory cytoselic gateway for the transport of fatty acids and hypolipidemic drugs into the nucleus, and their direct interaction with PPARs.
7. Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002; 22:5114-5127. A paper addressing the question of the mechanism by which the lipophilic ligands of nuclear receptors, which are poorly soluble in water, reach the nucleus to bind to their cognate receptors and initiate their transcriptional activity.
8. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108:465-474. An excellent review of the current opinions on the mechanism of action of nuclear receptors in association with their numerous co-regulators, with an attempt to define future goals towards which the field is striving.
9. Surapureddi S, Yu S, Bu H, et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A 2002; 99:11836-11841.
10. Mueller E, Drori S, Aiyer A, et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 2002; 277:41925-41930.
11. Krogsdam AM, Nielsen CA, Neve S, et al. Nuclear receptor corepressor-dependent repression of peroxisome proliferator-activated receptor delta-mediated transactivation. Biochem J 2002; 363:157-165.
12. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 2002; 99:2613-2618.
13. Escher P, Braissant O, Basu-Modak S, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142:4195-4202.
14. Michalik L, Desvergne B, Dreyer C, et al. PPAR expression and function during vertebrate development. Int J Dev Biol 2002; 46:105-114.
15. Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20:5119-5128.
16. Michalik L, Desvergne B, Tan NS, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 2001; 154:799-814. A study on unpredicted roles of PPARα and PPARβ in adult mouse epidermal repair. A clear demonstration that these two isotypes have non-redundant complementary functions in the inflammatory and re-epithelialization phase of wound-healing, respectively.
17. Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002; 99:303-308. This work on the analysis of mice, in which the PPARβ gene was disrupted by homologous recombination, provides evidence for the implication of this receptor in biological processes extending beyond lipid metabolism into placentation.
18. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473:333-336.
19. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001; 98:5305-5311. An elegant paper based on cell culture work and the treatment of obese rhesus monkeys with an isotype selective agonist of PPARβ, which suggests that such ligands are likely to have beneficial effects on reverse cholesterol transport from peripheral tissues and decrease the risk of cardiovascular disease associated with metabolic syndrome X.
20. Holst D, Grimaldi PA. New factors in the regulation of adipose differentiation and metabolism. Curr Opin Lipidol 2002; 13:241-245.
21. Vosper H, Patel L, Graham TL, et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 2001; 276:44258-44265.
22. Lee CH, Evans RM, Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis. Trends Endocrinol Metab 2002; 13:331-335.
23. Saluja I, Granneman JG, Skoff RP. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001; 33:191-204.
24. Tan NS, Michalik L, Noy N, et al. Critical roles of PPARbeta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15:3263-3277. A study on the response of keratinocytes to inflammatory signals produced after an injury. In these cells, TNF-α upregulates PPARβ via the stress kinase signalling pathway and triggers the production of ligands for the receptor, which among other functions, protects the cells from apopotosis.
25. Di-Poi N, Tan NS, Michalik L, et al. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002; 10:721-733. Based on a thorough analysis of the transcriptional action of PPARβ in keratinocytes, a model is presented for the anti-apoptotic role of this receptor. It underscores the close functional interaction between PPARβ and the Akt1 cell survival pathway, which PPARβ controls both at the transcriptional and posttranslational levels.
26. Hao CM, Redha R, Morrow J, et al. Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 2002; 277:21341-21345.
27. Hellemans K, Michalik L, Dittié A, et al. PPARβ contibutes to enhanced hepatic stellate cell proliferation. Gastroenterology 2003; 184-201.
28. Zhang J, Fu M, Zhu X, et al. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002; 277:11505-11512.
29. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99:335-345.
30. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000; 97:13275-13280.
31. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001; 98:2598-2603. The paper provides evidence that PPARβ can affect tumorigenesis based on the proliferation potential of PPARβ wild-type and null cells grown as xenografts in nude mice. It proposes that pharmacological inhibitors of PPARβ may inhibit invivo tumour growth.